Positive testing for BRAF or RET/PTC mutation has been shown to be specific for a malignant outcome in 100% of cases, whereas RAS mutations have been detected in up to 48% of benign follicular adenomas, 57% of FTC, and 21% of PTC [36,37]. Here, RET is linked to neoplasm.